Opko Health OPK Pharmaceutical — Gross Profit
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Opko Health in its filing.
Tagged under the XBRL concept us-gaap:GrossProfit.
The official record: Opko Health’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Opko Health's pharmaceutical — gross profit.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Opko Health's pharmaceutical — gross profit?
- Opko Health (OPK) reported pharmaceutical — gross profit of $29.71M in Q1 2026.
- How has Opko Health's pharmaceutical — gross profit changed year-over-year?
- Opko Health's pharmaceutical — gross profit increased by 22.3% year-over-year, from $24.29M to $29.71M.
- What is the long-term trend for Opko Health's pharmaceutical — gross profit?
- Over 2 years (2023 to 2025), Opko Health's pharmaceutical — gross profit has grown at a -24.2% compound annual growth rate (CAGR), from $248.68M to $143.02M.
- What does pharmaceutical — gross profit mean?
- The residual profit earned by the pharmaceutical segment after deducting the direct costs of production from total segment revenue. It measures the core profitability and production efficiency of the pharmaceutical business before operating expenses.